Literature DB >> 10517171

Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor.

J L Chou1, Z Fan, T DeBlasio, A Koff, N Rosen, J Mendelsohn.   

Abstract

Non-transformed human breast epithelial cell line MCF10A is dependent on exogenous epidermal growth factor (EGF) for continued growth. Complete G1 arrest was rapidly induced following EGF deprivation. The cell cycle arrest was accompanied by increased levels of p27KIP1, a cyclin-dependent kinase inhibitor, and reduced level of cyclin D1. This was associated with strong inhibition of cyclin-dependent kinase 2 and cyclin D1-associated kinase activities. Introduction of exogenous cyclin D1 into MCF10A (MCF10AD1) cells resulted in an accelerated cell growth rate but did not confer colony-forming capacity. Cell cycle arrest was still achieved in MCF10AD1 cells following EGF deprivation. In the great majority of MCF10AD1 clones, accumulation in G1 phase was accompanied by reduced cyclin D1 and increased p27KIP1 protein levels. In two clones where cyclin D remained unchanged during G1 arrest, it was found that more cyclin D1 protein was bound to p27KIP1. The data demonstrate that ectopic expression of cyclin D1 alone could not transform MCF10A cells nor was it sufficient to prevent G1 arrest induced by EGF deprivation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517171     DOI: 10.1023/a:1006217413089

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Regulation of choline deficiency apoptosis by epidermal growth factor in CWSV-1 rat hepatocytes.

Authors:  Craig D Albright; Kerry-Ann da Costa; Corneliu N Craciunescu; Erich Klem; Mei-Heng Mar; Steven H Zeisel
Journal:  Cell Physiol Biochem       Date:  2005

2.  GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast.

Authors:  Eric R Prossnitz; Helen J Hathaway; Allison L Scaling
Journal:  Horm Cancer       Date:  2014-04-10       Impact factor: 3.869

Review 3.  Jeremiah Metzger Lecture. Targeted cancer therapy.

Authors:  J Mendelsohn
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

4.  PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells.

Authors:  Akihide Ryo; Yih-Cherng Liou; Gerburg Wulf; Masafumi Nakamura; Sam W Lee; Kun Ping Lu
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

5.  PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer.

Authors:  J S Yu; S Koujak; S Nagase; C-M Li; T Su; X Wang; M Keniry; L Memeo; A Rojtman; M Mansukhani; H Hibshoosh; B Tycko; R Parsons
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

6.  The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Authors:  Joseph P Garay; Bedri Karakas; Abde M Abukhdeir; David P Cosgrove; John P Gustin; Michaela J Higgins; Hiroyuki Konishi; Yuko Konishi; Josh Lauring; Morassa Mohseni; Grace M Wang; Danijela Jelovac; Ashani Weeraratna; Cheryl A Sherman Baust; Patrice J Morin; Antoun Toubaji; Alan Meeker; Angelo M De Marzo; Gloria Lewis; Andrea Subhawong; Pedram Argani; Ben H Park
Journal:  Breast Cancer Res       Date:  2012-02-09       Impact factor: 6.466

7.  Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity.

Authors:  B Liu; M Fang; M Schmidt; Y Lu; J Mendelsohn; Z Fan
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

8.  PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.

Authors:  Jessica Byerly; Gwyneth Halstead-Nussloch; Koichi Ito; Igor Katsyv; Hanna Y Irie
Journal:  Breast Cancer Res       Date:  2016-09-23       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.